4,099 Shares in Bio-Rad Laboratories, Inc. $BIO Purchased by Atlantic Union Bankshares Corp

Atlantic Union Bankshares Corp acquired a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the third quarter, Holdings Channel.com reports. The institutional investor acquired 4,099 shares of the medical research company’s stock, valued at approximately $1,149,000.

Other hedge funds have also added to or reduced their stakes in the company. Quent Capital LLC bought a new position in shares of Bio-Rad Laboratories during the 3rd quarter valued at approximately $25,000. Farther Finance Advisors LLC lifted its stake in Bio-Rad Laboratories by 52.9% in the third quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 36 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Bio-Rad Laboratories by 3,633.3% during the second quarter. Caitong International Asset Management Co. Ltd now owns 112 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 109 shares during the period. Geneos Wealth Management Inc. increased its position in Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after buying an additional 76 shares during the last quarter. Finally, CWM LLC increased its position in Bio-Rad Laboratories by 82.0% in the third quarter. CWM LLC now owns 202 shares of the medical research company’s stock worth $57,000 after buying an additional 91 shares during the last quarter. Institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Up 2.5%

BIO stock opened at $306.53 on Thursday. The company has a quick ratio of 3.94, a current ratio of 5.44 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $8.27 billion, a PE ratio of -12.61 and a beta of 1.18. Bio-Rad Laboratories, Inc. has a twelve month low of $211.43 and a twelve month high of $351.02. The stock has a 50-day simple moving average of $309.69 and a two-hundred day simple moving average of $299.35.

Analyst Upgrades and Downgrades

BIO has been the topic of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Wells Fargo & Company boosted their price objective on Bio-Rad Laboratories from $265.00 to $340.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Wall Street Zen upgraded shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Saturday, January 10th. Finally, Citigroup lifted their target price on shares of Bio-Rad Laboratories from $350.00 to $375.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bio-Rad Laboratories has a consensus rating of “Hold” and a consensus target price of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.